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BRIEF NOTE
Blockage of Immune Serum-Mediated Inhibition of Growth of Plasmodium falciparum
by Absorption With P. falciparum Antigens1
RICHARD HURLEY and JULIUS P. KREIER, Department of Microbiology, The Ohio State University, Columbus, OH 43210
ABSTRACT. This report describes a microtiter system that should be useful for making preliminary deter-
minations of which components of plasmodia may be useful as vaccines. The system is based on antigen-
mediated blockage of inhibition of plasmodial growth in culture by immune serum. The necessity for a
quantitative approach to the analysis is emphasized if reproducible results are to be obtained.
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INTRODUCTION
An important avenue of research for the development
of a vaccine to combat malaria is identification of the
antigens to which the host must respond to become im-
mune. This must finally be done by immunizing and
challenging susceptible primates and human volunteers
with the candidate vaccines, but an in vitro test of immu-
nogenicity would be a valuable adjunct to any vaccine
development program.
Immune serum inhibits the growth of Plasmodium fal-
ciparum in vitro (Green et al. 1981, Jensen et al. 1982,
Brown et al. 1983). Inhibition has been considered to be
by antibody-mediated mechanisms (Cohen et al. 1969,
Khusmith et al. 1982), and also by nonantibody-
mediated mechanisms (Clark et al. 1976, Ockenhouse
and Shear 1984). The nonantibody-mediated mech-
anisms appear to be a consequence of macrophage activa-
tion (Clark et al. 1981) and thus are not antigen-specific
and do not have an anamnestic component.
The nonantibody-mediated mechanisms of culture in-
hibition are irrelevant to the present study except to the
degree that if they were operative in the immune serum
used, they would interfere with the demonstration of
antigen blockage of antibody-mediated growth in-
hibition. This note is a report on preliminary research in
this area.
'Manuscript received 24 March 1986 and in revised form 6 May
1987 (#86-17BN).
MATERIALS AND METHODS
IMMUNE SERUM. A pool of immune serum was obtained from owl
monkeys (Aotus trivigatus) that were inoculated intraperitoneally re-
peatedly with P. falciparum that had been carried continuously in
culture according to published procedures (Trager and Jensen 1976).
The parasitized human erythrocytes that were used for immunization
were washed several times in physiological saline before being injected
into the monkeys. The monkeys had parasitemias following the first
two or three injections but recovered after chloroquin sulfate treat-
ment. Subsequent inoculations did not result in parasitemias. Serum
was collected from the monkeys after they had become immune, well
after the chloroquin treatments were completed. The serum was pool-
ed, heat-inactivated, and adsorbed repeatedly with human erythro-
cytes before being used.
TEST SYSTEM. A microtiter system was developed to test the
inhibitory properties of the immune serum. The parasite cultures were
propagated in 60-mm plastic Petri plates using RPMI 1640 with 10%
human serum and type O human erythrocytes at a 5% hematocrit.
When the cultures attained about 4 to 6% infected erythrocytes, the
infection level was adjusted to approximately 1% with fresh erythro-
cytes, and the cultures were allowed to develop overnight in a candle
jar at 37 C. The cells were then suspended in fresh medium, and
0.10 mL was seeded into wells of a 96-well, flat bottom, microtiter
plate. Thin films were prepared immediately from several wells to
determine the parasitemia at To; 0.1 mL of the serum to be tested was
added to the appropriate wells. The plates were incubated in a candle
jar for 36 h. The test was terminated, and films were prepared from
each well, fixed in methanol, and stained with Giemsa.
ANTIGEN PREPARATION. The Plasmodium falciparum antigen
used to block antibody-mediated inhibition of plasmodial growth was
prepared from a pool of red cells harvested from cultures that, when
combined, had a parasitemia of 6.1%. The cells were washed once in
RPMI 1640, and the pellet was suspended in four times its volume
of RPMI. The suspension of infected erythrocytes was dispensed into
1 mL glass vials and immersed directly into liquid nitrogen. A prep-
aration of normal, uninfected, human erythrocytes was treated in the
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same manner and frozen. Just before use, the antigens were disrupted
by freeze-thawing.
PROCEDURE FOR ABSORPTION OF IMMUNE SERUM. The absorp-
tion of the sera was accomplished by adding a volume of antigen
preparation, either lysed, infected erythrocytes (IRBC) or lysed, nor-
mal erythrocytes (NRBC), to an equal volume of the serum to be
tested and incubating the mixture overnight at 4°C. The sera were
then centrifuged to remove any particulate matter, and 0.1 mL of the
supernatant fluid was added to the microtiter wells. After 36 h of
incubation, thin smears were prepared and the percentages of para-
sitized erythrocytes were determined by examining at least
500 erythrocytes in thin films made from each of the wells. In addi-
tion to the wells containing immune monkey serum (IMS) absorbed
with IRBC and NRBC antigen, wells containing normal human
serum (NHS) and no supplemental serum served as parasite growth
controls.
DATA ANALYSIS. Standard independent two-sample tests for dif-
ferences between means and variances were used to determine whether
the two treatments, (i.e., absorption with normal erythrocyte antigen
or infected erythrocyte antigen) produced significant differences (Re-
mmington and Schork 1985).
RESULTS AND DISCUSSION
In preliminary experiments, we determined that the
variation in parasite counts between replicate wells in
treatment groups was greater if medium was changed
than if no medium change was made. We also deter-
mined that the cultures grew for 36 h if no medium
change was made, thus eliminating the necessity of re-
placing the growth medium and reducing variation and
culture manipulation (data not shown).
The pool of immune monkey serum was shown to
inhibit parasite growth in the microtiter system (Table 1,
Trial 1). Wells containing non-immune monkey serum
and human serum served as controls. The immune
monkey serum was strongly inhibitory, as there was no
increase in percent infected erythrocytes in the wells con-
taining 0.1 mL of the immune monkey serum.
The results obtained in the first absorption experiment
were encouraging (Table 1, Trial 2). The wells that re-
ceived 0.1 mL of IMS absorbed with IRBC antigen had
slightly higher reaction levels; that is, less inhibition
than those which received 0.1 mL IMS absorbed with
NRBC antigens. The results, although not statistically
significant, encouraged us to persist. We theorized that
while some of the inhibitory antibodies were removed
from the immune serum by the absorption with IRBC
antigen, perhaps there was insufficient antigen to remove
them all. We next titrated our antibody to determine the
minimum inhibitory dose, reasoning that if this amount
of antibody was absorbed with the plasmoidal antigen a
significant effect should be seen.
Dilutions of the immune monkey serum from 1:4 to
1:256 were prepared, absorbed with either NRBC lysate
or IRBC lysate, and 0.1 mL was added to wells in a
microtiter plate (Table 1, Trial 3)- The difference in
percent infected erythrocytes at 36 h between the wells
containing IMS absorbed with IRBC lysate and those
containing IMS absorbed with NRBC lysate increased
with increasing dilution through l/64 and then de-
creased at 1/256 at which point there was no inhibition
to block. The absorption study was then repeated twice
with serum diluted 1:64 (Table 1, Trials 4 and 5).
One-tenth mL of a 1:64 dilution of immune monkey
serum absorbed with IRBC antigen was significantly
(P < 0.01) less inhibitory than an equivalent amount of
immune monkey serum absorbed with NRBC antigen.
In conclusion, once the immune serum was diluted to
the minimum inhibitory level, the effects of antigen
absorption became evident. An absorption test such as
this is like a complement fixation test and will give
meaningful results only if all the reactants are properly
titrated before use. We have thus demonstrated that, if
properly run, a microtiter test can be used to evaluate
antigens for their ability to block immune serum-
mediated inhibition of P. falciparum growth in culture.
This assay may possibly provide an in vitro correlate for
vaccine evaluation and will provide another tool for study
of the antigenic makeup of P. falciparum.
TABLE 1.
Effects of dilution and absorption of immune serum with antigens on its ability to inhibit the growth of P. falciparum in culture.
Treatment
To
No serum added
Normal Human Serum (NHS)
NHS absorbed with lysed NRBC
NHS absorbed with lysed IRBC
Normal Monkey Serum (NMS)
Immune Monkey Serum (IMS)
IMS absorbed with lysed NRBC
IMS absorbed with lysed IRBC
1/4 IMS absorbed with lysed NRBC
1/16 IMS absorbed with lysed NRBC
1/64 IMS absorbed with lysed NRBC
1/256 IMS absorbed with lysed NRBC
1/4 IMS absorbed with lysed IRBC
1/16 IMS absorbed with lysed IRBC
1/64 IMS absorbed with lysed IRBC
1/256 IMS absorbed with lysed IRBC
Trial 1*
1.8 ± 0.18(3)**
4.0 ± 0.45(3)
6.2 ± 0.28(3)
3.1 ± 0.08(2)
1.6 ± 0.31(9)
Trial 2
1.0 ± 0.16(3)
3.3 ± 0.07(3)
31. ± 0.07(3)
4.2 ± 0.20(3)
3.3 ± 0.20(3)
0.76 ± 0.27(9)
1.1 ± 0.14(9)
Trial 3
1.1 ± 0.04(3) 1.2
3.2 ± 0.50(3) 2.8
2.9 ± 0.14(3) 5.2
0.20 ± 0.01(3) 0.21
0.70 ± 0.08(3)
1.3 ± 0.23(3)
2.2 ± 0.51(3) 2.0
3.1 ± 0.15(3)
0.9 ± 0.23(3)
1.8 ± 0.56(3)
2.9 ± 0.27(3) 3.3
3.3 ± 0.01(3)
Trial 4
(1)
± 0.05(3)
± 0.73(3)
± .0.01(3)
± 0.43(10)***
± 0.28(10)***
Trial 5
1.2 ± 0.06(3)
4.2 ± 0.05(3)
4.1 ± 0.22(3)
2.2 ± 0.24(10)***
3.7 ± 0.28(10)***
*See text for explanation of trials.
**X ± SD of % infected erythrocytes in wells (numbers in parentheses) at To or after 36-h incubation.
***There is significantly (P < 0.01) less inhibition after absorption with lysed IRBCs than after absorption with lysed NRBCs in Trials 4
and 5.
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